SRDX Stock Overview
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.
No risks detected for SRDX from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$37.82|
|52 Week High||US$62.27|
|52 Week Low||US$32.43|
|1 Month Change||-1.97%|
|3 Month Change||-12.17%|
|1 Year Change||-30.38%|
|3 Year Change||-7.62%|
|5 Year Change||39.56%|
|Change since IPO||830.95%|
Recent News & Updates
Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
While Surmodics, Inc. ( NASDAQ:SRDX ) might not be the most widely known stock at the moment, it saw significant share...
|SRDX||US Medical Equipment||US Market|
Return vs Industry: SRDX underperformed the US Medical Equipment industry which returned -24.7% over the past year.
Return vs Market: SRDX underperformed the US Market which returned -21.2% over the past year.
|SRDX Average Weekly Movement||6.4%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SRDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SRDX's weekly volatility (6%) has been stable over the past year.
About the Company
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications.
Surmodics Fundamentals Summary
|SRDX fundamental statistics|
Is SRDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SRDX income statement (TTM)|
|Cost of Revenue||US$69.92m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.75|
|Net Profit Margin||-10.80%|
How did SRDX perform over the long term?See historical performance and comparison
Is SRDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRDX?
Other financial metrics that can be useful for relative valuation.
|What is SRDX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SRDX's PS Ratio compare to its peers?
|SRDX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NNOX Nano-X Imaging
SGHT Sight Sciences
OFIX Orthofix Medical
BFLY Butterfly Network
Price-To-Sales vs Peers: SRDX is good value based on its Price-To-Sales Ratio (5.5x) compared to the peer average (50.2x).
Price to Earnings Ratio vs Industry
How does SRDX's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: SRDX is expensive based on its Price-To-Sales Ratio (5.5x) compared to the US Medical Equipment industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is SRDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.5x|
|Fair PS Ratio||1.4x|
Price-To-Sales vs Fair Ratio: SRDX is expensive based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Share Price vs Fair Value
What is the Fair Price of SRDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRDX ($37.82) is trading above our estimate of fair value ($35.23)
Significantly Below Fair Value: SRDX is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRDX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Surmodics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SRDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SRDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SRDX's revenue (13.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: SRDX's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRDX's Return on Equity is forecast to be low in 3 years time (7.2%).
Discover growth companies
How has Surmodics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRDX is currently unprofitable.
Growing Profit Margin: SRDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRDX is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare SRDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: SRDX has a negative Return on Equity (-7.86%), as it is currently unprofitable.
Discover strong past performing companies
How is Surmodics's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SRDX's short term assets ($64.7M) exceed its short term liabilities ($28.4M).
Long Term Liabilities: SRDX's short term assets ($64.7M) exceed its long term liabilities ($22.6M).
Debt to Equity History and Analysis
Debt Level: SRDX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SRDX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SRDX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if SRDX's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Surmodics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRDX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SRDX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Maharaj (59 yo)
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD2.94M) is about average for companies of similar size in the US market ($USD2.92M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
Experienced Management: SRDX's management team is considered experienced (4.2 years average tenure).
Experienced Board: SRDX's board of directors are seasoned and experienced ( 11.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Surmodics, Inc.'s employee growth, exchange listings and data sources
- Name: Surmodics, Inc.
- Ticker: SRDX
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$529.102m
- Shares outstanding: 13.99m
- Website: https://www.surmodics.com
Number of Employees
- Surmodics, Inc.
- 9924 West 74th Street
- Eden Prairie
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.